相关临床试验
548
61 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2001
进行中（未招募）
26
4.7%
Available
1
0.2%
已完成
288
52.5%
Enrolling By Invitation
5
0.9%
尚未招募
30
5.5%
招募中
70
12.8%
暂停
1
0.2%
终止
24
4.4%
Unknown
79
14.4%
撤回
24
4.4%
暂无批准数据
- Dr. Brad Nelson has been named B.C. Cancer Victoria's Lynda and Murray Farmer Immunotherapy Research Chair through a $2-million donation, enabling expansion of CAR-T cell clinical trials for aggressive cancers. - The CLIC-01 trial demonstrated a 43% complete remission rate in leukemia and lymphoma patients who had exhausted all other treatment options. - The newly launched CLIC-02 trial targets different proteins on blood cancer cells, while CLIC-03 will focus on solid tumors like ovarian and pancreatic cancers starting in early 2027. - B.C. Cancer's immunotherapy program ranks among Canada's top two T-cell therapy programs alongside Princess Margaret Cancer Centre in Toronto.
• A randomized, double-blind, placebo-controlled trial (TACT) assessed tranexamic acid (TXA) in patients undergoing radical cystectomy for bladder cancer. • The study found that TXA did not significantly reduce the need for red blood cell transfusions within 30 days post-surgery compared to placebo. • Secondary outcomes, including blood loss and thromboembolic events, also showed no significant differences between the TXA and placebo groups. • The findings suggest that routine use of TXA during open radical cystectomy for bladder cancer is not recommended.
